trending Market Intelligence /marketintelligence/en/news-insights/trending/mPIW_swjNt0QT3-9VhWXVQ2 content esgSubNav
In This List

GlycoMimetics' leukemia drug shows high remission rates in phase 1/2 trial


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

GlycoMimetics' leukemia drug shows high remission rates in phase 1/2 trial

GlycoMimetics Inc.'s drug candidate GMI-1271 showed high remission and low mortality rates in patients with acute myeloid leukemia in the phase 2 portion of its ongoing phase 1/2 clinical trial.

The trial showed that patients treated with GMI-1271 together with standard chemotherapy continue to achieve higher-than-expected remission rates based on historical controls, as well as lower-than-expected induction-related mortality rates. Treatment also continues to be well tolerated in 79 patients.

Data showed that among 54 relapsed/refractory acute myeloid leukemia patients, the overall response rate was 41% and the 60-day induction related mortality rate was 7%. The median overall survival time for phase 1 trial patients was 7.6 months.

Remissions were durable enough to allow 9 patients to receive stem cell transplants. More than half of patients who responded with a remission survived for at least a year after treatment.

Oral mucositis, or inflammation with mouth ulcers that is a sign of adverse effects of chemotherapy, was seen at low rates and severity with only one grade 3/4 event observed.

Further, among 25 newly diagnosed elderly patients, the overall response rate was 68%, with 73% in patients with de novo acute myeloid leukemia and 64% in patients with secondary acute myeloid leukemia.

The 60-day mortality rate was 8% and there were no cases of grade 3 or 4 mucositis.

For nine evaluable patients achieving complete remission or complete remission with incomplete marrow recovery, disease-free survival was 100% at six months after treatment.

GlycoMimetics submitted the data from the trial to the U.S. Food and Drug Administration. In May, the FDA granted GMI-1271 breakthrough therapy designation for the treatment of adult patients with relapsed/refractory acute myeloid leukemia.

The agency also granted fast-track status to the drug candidate. In addition, GMI-1271 has been granted orphan drug designation by the FDA and the European Commission.